I think it has both implications for the civilian setting, particularly in longer transport or resource-limited areas," Dr. Adit Ginde said.

Viking Therapeutics, Inc. aces hurdles for obesity drug VK2735 vs. Zepbound/Wegovy—tolerability, weak differentiation, and competition. Click for this VKTX update.

Ozempic and similar weight loss drugs offer major benefits for obesity and heart health, but side effects, muscle loss, and ...

As Neurocrine enters 2026, our foundation is stronger than at any point in our more than 30-year history and it continues to strengthen, with growing enterprise-wide momentum and strategic and ...

Individual-level attribution modeling reveals that real-world semaglutide effectiveness is not a fixed property of the molecule, but an interaction between pharmacological exposure and modifiable care ...

Altimmune, Inc. closed a $75 million direct offering to fund Phase 3 pemvidutide trials for MASH. Learn more about ALT stock ...

The global market for synthetic chemicals is witnessing a strategic realignment, driven by shifting supply chains, heightened ...

An informational overview of reported February 2026 developments, FDA-approved vs. compounded medication distinctions, Wegovy pill category context, published pricing disclosures, telehealth ...

HCM is a genetic disease, usually caused by mutations in sarcomere proteins such as myosin, actin, tropomyosin, and myosin-binding protein C.

SARASOTA, FL, UNITED STATES, January 28, 2026 / EINPresswire.com / — Identifyn ®, a leader in super-resolution applications ...

Pfizer Inc. (NYSE:PFE) Q4 2025 Earnings Call Transcript February 3, 2026 Pfizer Inc. beats earnings expectations. Reported ...

Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 2b VESPER-3 study investigating monthly maintenance dosing of its ...